Actinium Pharmaceuticals
ATNM
60 hedge funds and large institutions have $7.36M invested in Actinium Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0.84% more ownership
Funds ownership: 16.5% → 17.34% (+0.84%)
2% less funds holding
Funds holding: 61 → 60 (-1)
11% less capital invested
Capital invested by funds: $8.23M → $7.36M (-$878K)
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$170K |
| 2 |
Renaissance Technologies
New York
|
+$149K |
| 3 |
Goldman Sachs
New York
|
+$103K |
| 4 |
Squarepoint
New York
|
+$95.9K |
| 5 |
B
Bailard
Foster City,
California
|
+$84.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$185K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$42.1K |
| 3 |
Two Sigma Investments
New York
|
-$35.9K |
| 4 |
GS
Gagnon Securities
New York
|
-$35.7K |
| 5 |
Millennium Management
New York
|
-$33.7K |
ATNM Hedge Fund Activity: Q4 2025 in Review
60 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2025, worth a combined $7.36M — down 11% from $8.23M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATNM positions and 8 closed out — a net gain of 1 holder — while 13 added to existing stakes and 19 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $170K. The largest seller was Citadel Advisors, exiting entirely with an estimated $185K sold.
- 60 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2025, down from 61 in Q3 2025.
- Funds reported $7.36M of Actinium Pharmaceuticals stock for Q4 2025, down 11% quarter-over-quarter.
- 9 funds opened new Actinium Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +1 holder.
- The largest Actinium Pharmaceuticals buyer in Q4 2025 was Acadian Asset Management, an estimated $170K added.
- The largest Actinium Pharmaceuticals seller in Q4 2025 was Citadel Advisors, an estimated $185K sold.
Based on aggregated 13F filings for Q4 2025.